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PRECLINICAL AND
CLINICAL IMAGING -
Rapid
Communication
Tumor-Specific Expression and Detection of a CEST
Reporter Gene
Il Minn,1 Amnon Bar-Shir,1,2 Keerthi Yarlagadda,1 Jeff W. M. Bulte,1,2
Paul B. Fisher,3,4,5 Hao Wang,6 Assaf A. Gilad,1,2 and Martin G. Pomper1,7*
Purpose: To develop an imaging tool that enables the detec-
tion of malignant tissue with enhanced specificity using the
exquisite spatial resolution of MRI.
Methods: Two mammalian gene expression vectors were cre-
ated for the expression of the lysine-rich protein (LRP) under
the control of the cytomegalovirus (CMV) promoter and the
progression elevated gene-3 promoter (PEG-3 promoter) for
constitutive and tumor-specific expression of LRP, respec-
tively. Using those vectors, stable cell lines of rat 9L glioma,
9LCMV-LRP and 9LPEG-LRP, were established and tested for
CEST contrast in vitro and in vivo.
Results: 9LPEG-LRP cells showed increased CESTcontrast com-
pared with 9L cells in vitro. Both 9LCMV-LRP and 9LPEG-LRP cells
were capable of generating tumors in the brains of mice, with a
similar growth rate to tumors derived from wild-type 9L cells. An
increase in CEST contrast was clearly visible in tumors derived
from both 9LCMV-LRP and 9LPEG-LRP cells at 3.4 ppm.
Conclusion: The PEG-3 promoter:LRP system can be used as
a cancer-specific, molecular-genetic imaging reporter system
in vivo. Because of the ubiquity of MR imaging in clinical prac-
tice, sensors of this class can be used to translate molecular-
genetic imaging rapidly. Magn Reson Med 74:544–549,
2015. VC 2015 Wiley Periodicals, Inc.
Key words: molecular imaging; chemical exchange saturation
transfer; PEG-3 promoter; glioma; magnetic resonance
imaging
INTRODUCTION
Molecular-genetic MRI uses reporter-imaging probe pairs
that can generate MR contrast (1). The goal of molecular-
genetic MRI is to leverage the superior three-dimensional
spatial resolution of MRI to develop reporter-based, tar-
geted MRI systems. Many reporters have been identified as
candidate MR contrast-generating genes. Those include:
the b-galactosidase-Gd3þ-containing galactopyranosyl ring
reporter-probe pair for T1 contrast (2); the tyrosinase-
paramagnetic iron pair for T2 contrast (3); the transferrin
receptor-monocrystalline iron oxide nanocompound pair
for T2 contrast (4); the ferritin and endogenous iron pair for
T2 contrast (5,6); the Mag A-iron pair for T2 contrast (7);
and, the secreted alkaline phosphatase (SEAP)-phospho-
rylated metalloporphyrin pair for T1 contrast (8). We have
developed an artificial gene, the lysine-rich protein (LRP),
as a reporter for chemical exchange saturation transfer
(CEST) MRI (9). The LRP provides a high density of amide
protons, which enables detection byMRIwithout requiring
administration of a cognate probe. LRP-expressing tumors
in themouse brain have been imaged by CESTMRI (9).
For imaging reporter genes to be applied in a target-
specific manner, they should either be delivered exclu-
sively to their targets or expressed specifically within
the target cells. The latter can be accomplished by using
a target-selective promoter to drive the expression of a
reporter following systemic delivery of a reporter plas-
mid. Many promoters of genes with elevated expression
in human cancers have been examined as potential
cancer-specific promoters, but most are active only in
cancers of certain tissues of origin (10,11). The optimal
promoters for cancer-specific, molecular-genetic imaging
would be active in a variety of human cancers, while
remaining minimally active or silent in normal tissues.
We have identified a minimal promoter from a rodent
gene, the progression elevated gene-3 (PEG-3 promoter),
through subtraction hybridization while searching for
genes involved in malignant transformation and tumor
progression (12). We found that the PEG-3 promoter
behaves as a cancer-specific promoter as it is active in a
variety of human cancers, including brain, prostate,
breast, pancreatic, and skin cancers, with minimal activ-
ity in normal counterpart tissues (13–16). Tumor speci-
ficity of the PEG-3 promoter has been attributed to
binding sites of two transcription factors, AP-1 and PEA-
3 (or E1AF, the human homolog), which are reported to
be overexpressed in human cancer cells (13). Systemic
delivery of the PEG-3 promoter-reporter plasmid
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followed by imaging with bioluminescence or single
photon emission computed tomography (SPECT) enabled
detection of micrometastases in experimental models of
human breast cancer and melanoma (17). However, biolu-
minescence imaging cannot extend beyond preclinical
models and SPECT is fraught with relatively low spatial
resolution. Accordingly we turned to MRI with the PEG-3
promoter to drive production of LRP in a cancer-specific
manner with the high spatial resolution of this modality.
The LRP is based on CEST, a relatively new MR
contrast mechanism (18–20). CEST allows detection of
bioorganic molecules, such as proteins (21,22), polysac-
charides (23,24), metabolites (25–27), enzyme substrates
(28–31) as well as injectable compounds (32) due to the
exchange of MR-saturable, labile protons in these mole-
cules with those of water. Here, we present a molecular-
genetic imaging approach to detect tumor-specific gene
expression in an animal model of glioma by using the
MR reporter gene LRP and CEST MRI. The LRP was
expressed under control of the tumor-specific PEG-3 pro-
moter in rat 9L glioma cells (9LPEG-LRP). 9LPEG-LRP cells
transplanted to a mouse brain showed higher CEST con-
trast compared with that from similarly transplanted
wild-type cells. Our results demonstrate the feasibility of
using a CEST-based reporter gene under a tumor-specific
promoter for detection of tumors in vivo with MRI.
METHODS
In Vitro Assessment of PEG-Promoter Activity
The dual-luciferase assay was carried out to measure
promoter activities in rat 9L glioma cells. 9L cells were
grown in RPMI 1640 supplemented with 10% fetal
bovine serum and 1 penicillin and streptomycin in a
humidified incubator (37C, 5% CO2). 9L cells were
seeded in 24-well plates (1  105 cells per well). Forty-
eight hours later, cells were transiently transfected with
the following combination of plasmids using jetPRIMEV
R
according to the manufacturer’s instructions (Polyplus-
Transfection Inc., Illkirch, France); (i) pPEG-Luc
(17)þpGL4.74 (Promega, Madison, WI), (ii) pCMV-Tri
(17)þpGL4.74, and (iii) pGL3-basic (Promega, Madison
WI)þpGL4.74 with a 10:1 ratio for each preparation.
pPEG-Luc possess PEG-3 promoter driven firefly lucifer-
ase (fLuc), pCMV-Tri has CMV promoter driven fLuc,
and pGL3-basic plasmid has no promoter, serving as a
promoterless control. pGL4.74 plasmid expresses Renilla
luciferase (rLuc) to normalized the transfection effi-
ciency. At 48 h post-transfection, fLuc activity was meas-
ured using the Dual-LuciferaseV
R
Reporter Assay System
(Promega). The fLuc activity was normalized to rLuc
activity and total protein amount measured by the
CoomasieV
R
protein assay reagent kit (Pierce Biotechnol-
ogy, Rockford, IL).
Cloning of the Expression Constructs
The pMONO-neo-mcs vector was purchased from
InvivoGen (San Diego, CA) and the ferritin heavy chain
core promoter was replaced with the PEG-3 promoter to
create pPEG-neo-mcs. Lysine-rich protein (LRP), which
consists of four repeats of ‘MGKKKKKKKKKKKKKKKKK
KKKKKKKGS’ and a V5 tag, was amplified by polymer-
ase chain reaction (PCR) using pLRP101 (9) as a template
and inserted into pPEG-neo-msc and pCEP4 (Life Tech-
nologies, Carlsbad, CA) to create pPEG-LRP and pCMV-
LRP, respectively. The sequence of the vector was con-
firmed (MacrogenUSA, Rockville, MD). Primers used for
PCR were as follows: PEG-3 Promoter for pPEG-neo-msc
(Forward: CAGAACTAGTAGAAAGAGAAAGAGAATGG-
GAC; Reverse: AAC AGGATCCGTCCGGTTCGGTTTGC
CAAAAGCG), LRP for pPEG-LRP (Forward: CTAAATCG
ATCCATCATTTGTACAAAAAAGCAGGCTCCG; Reverse:
AGCACCTAGGTTACTAACCGGTACGCGTAGAATCGAG),
LRP for pCMV-LRP (Forward: CAGTAAGCTTCCATCAT
TTGTACAAAAAAGCAGGCTCCG; Reverse: CACAATCTC
GAGTTAC TAACCGGTACGCGTAGAATCGAG).
Establishing a Stable Cell Line Expressing
pPEG-LRP and pCMV-LRP
9L cells were transfected separately with pPEG-LRP and
pCMV-LRP using Lipofectamine 2000 (Life Technologies,
Carlsbad, CA) according to the manufacturer’s instruc-
tions. 9LPEG-LRP and 9LCMV-LRP were selected by main-
taining cells after the transfection in growth medium
containing 1 mg/mL of G-418 (Life Technologies, Carls-
bad, CA) and 100 mg/mL of Hygromycin B (Corning Cell-
gro, Manassas, VA), respectively.
In Vitro CEST MRI
In vitro CEST MRI experiments were performed as previ-
ously described (33,34) with the following modifications.
In brief, 1  107 cells were placed in a 5 mm NMR tube
(three tubes from three separate preparations, for each
cell type, 9L or 9LPEG-LRP) and placed within a vertical-
bore 11.7T Bruker Avance system (Bruker Biosciences
Corp., Billerica, MA) at 37C. A modified RARE (repeti-
tion time/echo time [TR/TE]¼ 5000/20 ms, RARE
factor¼8, 1 mm slice thickness, field of view (FOV)¼ 1.7
 1.7 cm, matrix size¼ 128  64, resolution¼ 0.17 
0.34 mm, and NA¼ 2) sequence, including a magnetiza-
tion transfer (MT) module (B1¼ 3.6 mT/3000 ms) was
used to acquire CEST weighted images from 4.4 ppm
to þ4.4 ppm (step¼ 0.2 ppm) around the water reso-
nance (0 ppm). For B0 shift correction of each pixel in
the CEST image, the absolute water resonant frequency
shift was measured using a modified Water Saturation
Shift Reference (WASSR) method (35), using the same
parameters as in CEST imaging except TR¼ 1500 ms, sat-
uration pulse of 500 ms, B1¼ 0.5 mT and a sweep range
from 1 ppm to 1 ppm (step¼ 0.1 ppm).
Animal Model
NOD/SCID/IL2rgnull (NSG) mice were purchased from
the Animal Resource Core of the Sidney Kimmel Com-
prehensive Cancer Center of Johns Hopkins. Mice were
anaesthetized by inhaling 1.5% isoflurane/oxygen gas.
Small holes were made on the skull at 2 mm lateral to
the bregma. 2  105 cells in 2 mL of media were directly
injected into the striatum 3 mm deep from the skull
using a 24 gauge Hamilton syringe over 5 min. Animal
experiments were performed in accordance with
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protocols approved by Johns Hopkins Animal Care and
Use Committee (ACUC).
In Vivo CEST MRI
Mice with bilateral tumors within striatum (9L and
9LPEG-LRP, n¼8) and (9L and 9LCMV-LRP, n¼1) were
used. Data were acquired using a horizontal-bore 11.7
Tesla (T) MRI scanner (Bruker Biospec) equipped with a
circular polarized MRI transceiver coil (ID¼23 mm).
Seven days after cell transplantation, mice were anesthe-
tized with 1.5% isoflurane and CEST data were obtained
as previously described (33,36), and with the following
parameters: A single 1 mm slice with FOV of 1.6 
1.6 cm2 and a 96  48 matrix were used, resulting in an
in-plane resolution of 0.167  0.333 mm. CEST-weighted
images were acquired with a modified RARE pulse
sequence (TR/TE¼6000/35 ms), using a 3.6 mT/3000 ms
saturation pulse from 4.2 to þ4.2 ppm (0.2 ppm steps)
around the water resonance, which was assigned to be at
0 ppm (total experimental time of 41 min). Pixel-based
B0 correction was used as described before (35) using the
same parameters as above except for TR¼1500 ms, B1/
tsat¼ 0.5 mT/500 ms, with a sweep range from 1 to þ1
ppm (0.1 ppm steps). Mean CEST spectra (Z-spectra)
were plotted from a region of interest (ROI) for each
tumor and normal brain tissue, after B0 correction.
CEST Data Processing
Data processing was performed using custom-written
scripts in Matlab as described earlier (33). Mean Z-
spectra were used from a ROI for each sample, after B0
correction for each voxel. MTRasym¼ 100  (S-Dv  SDv)/
S0 was computed at different offsets, Dv. To remove
magnetization transfer effects, DMTRasym was defined as
[MTRasym (tumor)]  [MTRasym (normal brain tissue)], as
previously described (37).
Statistical Analyses
Because a series of frequencies was applied to the same
sample in the in vitro CEST MRI, the generalized esti-
mating equation (GEE) approach (38) was used to take
into account the correlations across the frequencies
when we compared the CEST contrast in 9L and 9LPEG-LRP
cells, and P values of the score test were reported. The
GEE method was also applied to the comparisons in the in
vivo CEST MRI study to account for the correlations arising
from the fact that paired data of 9L and 9LPEG-LRP cells
were collected from the same mouse and each was meas-
ured with a series of frequencies. All the tests were two-
sided. The analysis was performed using software SAS
(version 9.4, Cary, NC)
RESULTS
We first examined whether the PEG-3 promoter was
active in the 9L cell line. After transient transfection of
9L cells with pGL3-basic (no promoter control), pPEG-
Luc (17), and pCMV-Tri (17), we measured fLuc activity
driven by each promoter. The PEG-3 promoter showed
activity comparable to one third of that of the CMV pro-
moter in 9L cells (Fig. 1).
To develop cell lines that stably express LRP, we cre-
ated two mammalian expression vectors for constitutive
(pCMV-LRP) and tumor-specific (pPEG-LRP) gene
expression. The pCMV-LRP construct was equipped with
the CMV promoter and the hygromycin B resistance
gene. The pPEG-LRP construct was equipped with the
tumor-specific PEG-3 promoter and the neomycin resist-
ance gene. To enhance the relatively weak activity of the
PEG-3 promoter compared with the CMV promoter
(Fig. 1), an SV40 enhancer and an SV40 polyadenylation
site were inserted upstream and downstream of the PEG-
3 promoter:LRP construct, respectively. After transfecting
rat 9L glioma cells with those vectors, we selected cells
expressing LRP by maintaining them in media contain-
ing hygromycin B and G418 and used surviving cells
(9LCMV-LRP and 9LPEG-LRP) for further study. We per-
formed in vitro CEST MRI to test whether the LRP
expressing cells generated CEST contrast. 9LPEG-LRP cells
showed increased CEST contrast compared with 9L cells
at 3.3–3.9 ppm, the frequency at which the original LRP
generated contrast (9) (Fig. 2).
We then developed murine glioma models to test LRP
in vivo. 9L, 9LCMV-LRP, and 9LPEG-LRP cells were capable
FIG. 1. a–e: Schematic diagram of the plasmids used. Promoter-less pGL3-basic (a), pPEG-fLuc (b), pCMV-Tri (showing only the fLuc
expression cassette) (c), pCMV-LRP (d), and pPEG-LRP (e). f: PEG-3 promoter is active in the rat 9L glioma cell line. Relative activities
of PEG-3 promoter and CMV promoter in 9L cells were measured by the dual luciferase assay after transient transfection. Firefly lucifer-
ase activity was normalized to that of renilla luciferase and to total protein. Error bars represent standard deviation, n¼3. fLuc: firefly
luciferase, V5: V5 tag.
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of forming tumors in the brains of immunocompromised
NSG mice, as shown by T2-weighed MRI (Figs. 3a,c). An
increase in CEST contrast was visible in tumors derived
from both 9LCMV-LRP and 9LPEG-LRP cells compared with
wild-type 9L tumors, as shown in Figs. 3b,d. We imaged
a total of eight mice harboring 9L (left) and 9LPEG-LRP
(right) in the brain. The average CEST contrast, i.e.,
DMTRasym value, was significantly higher (P< 0.01;
n¼ 8) for tumors derived from cells expressing LRP than
from the wild-type 9L tumors at 3.4 ppm (Figs. 3e,f).
These results demonstrate that a CEST reporter gene can
be expressed in vivo in a tumor-specific manner and can
be used as a tumor-specific biomarker for MR
applications.
DISCUSSION
In this preclinical study, we present proof-of-principle
for cancer-specific CEST MRI using reporter-based,
molecular-genetic imaging. Many reporter genes that pro-
duce MR contrast for imaging have been identified and
have shown promising characteristics for MR-based
molecular-genetic imaging (10,39,40). To apply those
reporters to the clinic, they should be selectively
expressed in target cells, namely, cancer. Targeted deliv-
ery and selective transfection of reporter plasmid is a
challenging task, especially for small or micrometastatic
lesions. Using a target-specific promoter to control the
expression of a reporter at the target is an alternative
approach, which we have chosen. The optimal promoter
for cancer-specific imaging would be robustly active in a
wide variety of human cancers, while remaining inactive
or minimally active in normal tissue. We leveraged the
well-studied, cancer-specific PEG-3 promoter to drive
the expression of the synthetic CEST probe, LRP. We
have shown that the PEG-3 promoter is active in all
FIG. 2. 9L cells overexpressing LRP generate CEST contrast in
vitro. Rat 9L glioma cells stably expressing PEG-prom-driven LRP
were generated to provide 9LPEG-LRP. a: In vitro CEST contrast in
9L vs. 9LPEG-LRP cells. b: The generalized estimating equation
(GEE) approach demonstrated a difference in CEST contrast
between wild-type and gene-tagged cells at 3.7 ppm, n¼3.
FIG. 3. PEG-3 promoter:LRP exhibited CEST contrast in a murine model of rat 9L glioma. Representative T2-weighted (a,c) and CEST
images superimposed on T2-weighted images (b,d). The left hemisphere harbors the gene-tagged 9L tumor, namely, CMV-LRP in (a)
and (b) and PEG-LRP in (c) and (d), while the right hemisphere has a tumor derived from implantation of wild-type 9L cells. Note that
PEG-LRP enables CEST imaging due to the activation of PEG-3 promoter by transcription factors present in the 9L tumor cells. Tempo-
ral changes in the DMTRasym values of each tumor type (e). The generalized estimating equation (GEE) approach demonstrated differ-
ence in CEST contrast at 3.4 ppm between tumors derived from wild-type (9L) and gene-tagged (9LPEG-LRP) cells (f). The scale in (b and
d) is of MTRasym and in (e) the scale is of DMTRasym. Mean6 standard deviation; n¼8.
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human cancer types tested and is minimally active in
the corresponding normal tissues (8,9,12). Because the
PEG-3 promoter originated from a rodent genome, and
humans do not have the orthologous gene, there is very
little possibility of unwanted chromosomal insertion
through homologous recombination. In addition, the rel-
atively small size of the PEG-3 promoter (465 base pairs)
will be an advantage for designing smaller imaging vec-
tors for improved transfection efficiency (41).
The LRP does not require additional administration of
the probe because the amide protons from the lysine
residue are the source of CEST contrast. PEG-3 promoter-
driven LRP expression with the SV40 enhancer in
animal models of glioma was sufficient to generate
detectable CEST contrast.
We designed the pPEG-LRP vector to be suitable for
systemic delivery and clinical translation. The vector has
the clinically compatible kanamycin resistance marker
for the production of the plasmid (42). Additionally, the
pPEG-LRP has a small size of 3575 base pairs, which can
enable enhanced transfection efficiency (41). The present
study demonstrated limited CEST contrast from LRP,
potentially due to weak promoter activity of tumor-
specific PEG-3 promoter. Further modifications of the
small pPEG-LRP plasmid to augment the expression of
LRP would enhance the sensitivity of detection. For
example, a two-step transcriptional amplification system
can be introduced to increase the number of LRP mole-
cules expressed (11,43). Adding scaffold/matrix attach-
ment regions (S/MARs) to the plasmid will enable
prolonged maintenance of the plasmid, resulting in accu-
mulation of LRP within the transfected cancer cells.
Also, using longer LRP would enhance CEST contrast.
Indeed, CEST imaging using traditional pulse sequences,
as in this study, is limited by low sensitivity, manifested
by only a few percent change in contrast, especially for
biological samples. This is also true for the LRP. As
shown above, only a small yet significant (P<0.01)
change was observed. In a similar case, where LRP was
used to monitor Oncolytic Virotherapy (44), a significant
change was detected; however, it was on the same order
of magnitude as described here. Nevertheless, CEST is
an evolving field of MRI and new techniques that can
improve the sensitivity are constantly under develop-
ment, including methods for isolating the CEST signal
from rapidly exchanging protons such as through length
and offset varied saturation (LOVRS) (45), frequency-
labeled exchange (FLEX) (46) as well as through separa-
tion of the contrast from endogenous contrast from
proteins or magnetization transfer contrasts (47).
The PEG-3 promoter:LRP system enabled cancer-
specific imaging using CEST MR in vivo in the rat 9L gli-
oma model. Efforts to extend those findings to experi-
mental models of human cancer in the periphery, with a
focus on systemic delivery of the plasmid to detect meta-
static disease, are under way.
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